The high clinical and economic burdens associated with cardiometabolic conditions, including cardiovascular disease, diabetes, and obesity, in the United States present ongoing challenges for patients, providers, payers, drug manufacturers, and the entire healthcare system.
Impact of the New ACC/AHA Guidelines on the Treatment of High Blood Cholesterol in a Managed Care Setting
Paul S Chan, MD, MSc, Heidi C. Lew, PharmD, Toros Cagla PhD, Brian K. Solow, MD, FAAFP, Karen M. Stockl, PharmD, Josephine N. Tran, PharmD, MS
In November 2013, the American College of Cardiology (ACC) and the American Heart Association (AHA) released together new clinical guidelines for the treatment of patients with high blood cholesterol. The 2013 guidelines provide a new paradigm for cholesterol management in the primary and secondary prevention of coronary artery disease (CAD)
Real-World Consequences of the 2013 ACC/AHA Cholesterol Guidelines for the Prevention of Cardiovascular Disease
Utilization of Parenteral Anticoagulants and Warfarin: Impact on the Risk of Venous Thromboembolism Recurrence in the Outpatient Setting
Jennifer Cai, MS, MPH, Winghan Jacqueline Kwong, PharmD, PhD, Ronald Preblick, PharmD, MPH, Qiaoyi Zhang, MD, PhD
Venous thromboembolism (VTE) encompasses deep-vein thrombosis (DVT) and pulmonary embolism (PE). VTE is a chronic disease that is associated with a high risk for recurrence, especially during the initial months of therapy.
Better Compliance with Clinical Guidelines for Venous Thromboembolism Can Improve Patient Outcomes, Reduce Costs
Charles Jia-Haur Hu, DO, Chihyi Lin, DO, Brien Rex Miller, DO, Hanh Nguyen, DO, Quang T. Nguyen, DO, FACP, FACE, FTOS
Type 2 diabetes mellitus is an ongoing medical problem that clinicians deal with on a daily basis. The necessity of treating diabetes adequately is essential because of the many comorbidities and complications associated with uncontrolled diabetes.
Addressing Adherence a Key Challenge in the Management of Patients with Type 2 Diabetes
Results 1 - 5 of 5